Vyriad
Dr. Peng is responsible for preclinical discovery, clinical correlatives and analytical methods in GMP virus manufacturing at Vyriad. Internationally known for her pioneering work in virus engineering and translational sciences, she also leads a research team at Mayo Clinic as Professor of Oncology and directs the Virus and Gene Therapy Toxicology and Pharmacology Core. Dr. Peng received her PhD in Gene Therapy at Cambridge University, UK, has published more than 100 scientific papers, holds numerous honors and awards, including the Young Investigator award from the Alliance for Cancer Gene Therapy. She is a strong advocate for the field of oncolytic virotherapy in her various roles in professional organizations.
Vyriad
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.